ADVERTISEMENT
Sana Biotechnology appoints Dhaval Patel as chief scientific officer
Dhaval Patel will advance Sana's clinical pipeline, focusing on autoimmune diseases, type 1 diabetes, and innovation
Dhaval Patel. / Image – UCB
Seattle-based cell engineering company, Sana Biotechnology announced the appointment of prominent drug developer Dhaval Patel as executive vice president and chief scientific officer. The company focuses on developing engineered cells as medicines, with ongoing clinical trials targeting various autoimmune diseases, type 1 diabetes, and blood cancers.
Patel has extensive experience in immunology and autoimmune diseases, and his appointment comes as the company looks to advance its clinical pipeline and maximize the potential of its engineered cell therapies.
Acknowledging Patel’s significant experience in the field, Steve Harr, Sana’s president and CEO stated, “We are thrilled to welcome Dhaval to Sana’s senior leadership team and look forward to partnering with him to build the company, maximize the value of our current pipeline, and secure our long-term future.”
“His expertise in immunology and autoimmune diseases make him ideally suited to help advance our clinical pipeline, particularly for B-cell mediated autoimmune diseases and type 1 diabetes, and accelerate our innovation,” the CEO further added.
Before joining Sana, Patel served as executive vice president and chief scientific officer at UCB, where he played a pivotal role in the registration of key therapies. He also spent a decade at Novartis, where he led research efforts in autoimmune and inflammatory diseases, contributing to the development of multiple therapies.
Patel’s career also includes roles as an eminent professor of medicine at the University of North Carolina and chief of the division of allergy and immunology at Duke University.
Patel expressed enthusiasm about joining Sana during a period of growth, stating, “I am delighted to join Sana at this exciting time of growth. Our hypoimmune platform provides a unique opportunity to push the boundaries of science and transform the future for patients. With four ongoing clinical trials across seven indications we are poised to take a significant step forward in the company’s mission to bring innovative, life-changing therapies to patients in need. I am eager to collaborate with this talented team to accelerate our journey towards groundbreaking advancements and real-world impact.”
He holds an M.D. and Ph.D. in microbiology and immunology from Duke University and is board certified in internal medicine, rheumatology, and allergy and immunology.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
.png)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login